APLN and cancer: The important data from Uribesalgo et al, summarized in Fig 1, provide a foundation for the development of guidelines for personalized treatment of cancer such as in the breast and lung where anti‐angiogenic therapy should be used preferentially on patients carrying tumors expressing low levels of Apelin.